Fundraising Fox
/Companies
Sign in

SymKardia

Westlake, US · Founded 2024 · Delaware corporation

Find your way into SymKardia

Sign up to see every warm intro you have to SymKardia

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the SymKardia team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

SymKardia develops a selective cardiac neuromodulation therapy to treat cardiac arrhythmias such as atrial fibrillation, targeting the nervous system rather than only cardiac tissue. It is a clinical-stage cardiovascular medical device company running pre-clinical and clinical research programs.

BiotechHealthtechMedical Devices

Founders & leadership

SGSteven Girouard
Steven GirouardExecutive
JPJonathan Piccini
Jonathan PicciniExecutive
DSDwight Skinner
Dwight SkinnerChief Operating OfficerDwight Skinner has over 25 years of experience in medical device product development, with expertise in implantable electrical stimulation systems, cardiac leads, and neuromodulation therapies. He holds a Design for Six Sigma Master Black Belt certification and brings knowledge of regulatory and manufacturing standards including ISO 10993 biocompatibility and MRI safety.
ILImad Libbus
Imad LibbusChief Scientific Officer
BKBruce KenKnight
Bruce KenKnightChief Executive Officer
AC
Anthony CaparsoExecutive

Board

RP
Robert PicarelBoard director
CR
Claudio RumazzaBoard director
AS
Arun SridharBoard director
AG
Alain Garcinuno ColletBoard director
JB
James BlouzardBoard director

Reported raises · per SEC filings

Form D private placements

$8.3M disclosed across 2 rounds · 2025–2026

▶$4.3MraisedOct 2026 · 3 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Anthony CaparsoExecutive Officer, Director
  • Bruce KenKnightExecutive Officer
  • Steven GirouardExecutive Officer
  • Jonathan PicciniExecutive Officer
  • Imad LibbusExecutive Officer
  • Dwight SkinnerExecutive Officer
  • Robert PicarelDirector
  • Arun SridharDirector
  • Claudio RumazzaDirector
  • Alain Garcinuno ColletDirector
  • James BlouzardDirector
Offering amount
$12M
Amount sold
$4.3M
First sale
Jun 2026
Incorporated
Corporation, Delaware, 2024
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4MraisedOct 2026 · 8 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Anthony CaparsoExecutive Officer, Director
  • Bruce KenKnightExecutive Officer
  • Steven GirouardExecutive Officer
  • Jonathan PicciniExecutive Officer
  • Imad LibbusExecutive Officer
  • Dwight SkinnerExecutive Officer
  • Robert PicarelDirector
  • Arun SridharDirector
  • Claudio RumazzaDirector
  • Alain Garcinuno ColletDirector
  • James BlouzardDirector
Offering amount
$4M
Amount sold
$4M
First sale
Jan 2025
Incorporated
Corporation, Delaware, 2024
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 3

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Rf SurgicalMedtronic is a healthcare technology company that develops medical devices and technologies — including pacemakers, robotic-assisted surgery systems, and AI-driven health tools — used by doctors, scientists, and engineers to treat pain and disease. It works with clinicians to create solutions aimed at treating conditions such as AFib.
SyncardiaSynCardia manufactures the world's first commercially approved total artificial heart for patients with end-stage heart failure awaiting transplant. The company develops and delivers mechanical circulatory support devices as alternatives to heart transplantation for critically ill patients.

Companies working in the same space as SymKardia.

Frequently asked questions

What does SymKardia do?
SymKardia develops a selective cardiac neuromodulation therapy to treat cardiac arrhythmias such as atrial fibrillation, targeting the nervous system rather than only cardiac tissue. It is a clinical-stage cardiovascular medical device company running pre-clinical and clinical research programs.
How much funding has SymKardia raised?
SymKardia has disclosed $8.3M raised across 2 rounds.
Where is SymKardia headquartered?
SymKardia is headquartered in Westlake, US.